caa a22 4500 445795360 CHVBK 20180317145123.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1007/s10620-011-1869-6 doi (NATIONALLICENCE)springer-10.1007/s10620-011-1869-6 Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin [Elektronische Daten] [Christopher Moore, Magdalena George, David Van Thiel] Background: The response to pegylated interferon (peg-IFN) plus ribavirin therapy remains less than ideal with 40-50% of treated subjects failing to clear the virus. Moreover, retreatment is only minimally effective. Consensus interferon (c-IFN) has been shown to be efficacious in HCV genotype 1 patients who have failed therapy with peg-IFN. Aim: To evaluated the response to re-treatment of peg-IFN plus ribavirin partial-responders with c-IFN plus ribavirin. Methods: Forty-two subjects who had previously failed to clear virus after treatment with peg-IFN plus ribavirin were treated with c-IFN (15μg/day) plus ribavirin (800-1,200mg/day) until 12months of therapy or a total of six consecutive months of PCR negativity was achieved. Results: The study population consisted predominantly of males (71%), Caucasians (76%), with African Americans comprising the remaining 24%, subjects with HCV genotype 1 infection (81%) and 21% had cirrhosis by liver biopsy. The overall SVR rate was 29%. The only pretreatment variable that distinguished responders from partial-responders was the serum triglyceride level. Conclusions: The use of c-IFN plus ribavirin in the retreatment of prior peg-IFN plus ribavirin partial responders is essentially twice that achieved in prior re-treatment regimens consisting of a second course of peg-IFN plus ribavirin. These results will need to be evaluated against the use of triple therapy consisting of a peg-IFN plus ribavirin and a protease inhibitor. More studies utilizing c-IFN plus ribavirin with either a protease inhibitor or polymerase inhibitor need to be performed as well. Springer Science+Business Media, LLC, 2011 Consensus-interferon nationallicence HCV treatment nationallicence HCV re-treatment nationallicence Partial responders nationallicence Moore Christopher Rush University Medical Center, Suite 158 Professional Office Building, Chicago, IL, USA aut George Magdalena Rush University Medical Center, Suite 158 Professional Office Building, Chicago, IL, USA aut Van Thiel David Rush University Medical Center, Suite 158 Professional Office Building, Chicago, IL, USA aut Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/10(2011-10-01), 3032-3037 0163-2116 56:10<3032 2011 56 10620 https://doi.org/10.1007/s10620-011-1869-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10620-011-1869-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Moore Christopher Rush University Medical Center, Suite 158 Professional Office Building, Chicago, IL, USA aut NATIONALLICENCE 700 1- George Magdalena Rush University Medical Center, Suite 158 Professional Office Building, Chicago, IL, USA aut NATIONALLICENCE 700 1- Van Thiel David Rush University Medical Center, Suite 158 Professional Office Building, Chicago, IL, USA aut NATIONALLICENCE 773 0- Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/10(2011-10-01), 3032-3037 0163-2116 56:10<3032 2011 56 10620 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer